Appointment of Paul Brennan as Non-Executive Director

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Paul Brennan as an independent Non-Executive Director, effective March 16, 2022. Brennan's extensive healthcare experience includes his role as CEO of PolyNovo Limited, where he grew the company significantly. His appointment is expected to leverage Immuron's unique intellectual property in gut health and enhance its clinical research capabilities. Non-Executive Chairman Dr. Roger Aston expressed confidence in Brennan's diverse background, which includes technology commercialization and international marketing.

Positive

• Paul Brennan brings extensive healthcare experience, including previous leadership at PolyNovo Limited.
• Brennan's appointment is expected to enhance Immuron's strategic planning and international marketing efforts.
• His background in commercialization may unlock significant market opportunities for Immuron's gut health innovations.

Negative

• None.

MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today.

Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from $30M to a high of $2B. Prior to this Mr Brennan was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare for 6 years.

Commenting on his appointment, Paul Brennan said, “Immuron has unique intellectual property that places it at the forefront of gut health. This emerging field of medical advancement, coupled with Immuron’s strength in clinical research, should deliver significant market opportunity. I am looking forward to working closely with the team.”

Dr. Roger Aston, Non-Executive Chairman, said, “we are delighted with the appointment of Paul to the Board as he brings a diverse background including commercialisation of technology, company governance, strategic planning and international marketing and more.”

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT:

Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

For more information visit: http://www.immuron.com

FAQ

What is the significance of Paul Brennan's appointment to Immuron Limited?

Paul Brennan's appointment may strengthen Immuron's strategic planning and enhance its market position in gut health.

What experience does Paul Brennan bring to Immuron Limited?

Brennan has extensive healthcare experience, notably as CEO of PolyNovo Limited, and expertise in commercialization and international marketing.

When was Paul Brennan appointed as a Non-Executive Director of Immuron Limited?

Paul Brennan was appointed on March 16, 2022.

How might Paul Brennan's background impact Immuron Limited's future?

His diverse background may enhance Immuron's opportunities in clinical research and technology commercialization in gut health.